Product Name
Propranolol hydrochloride
Description
Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Structural Formula
Propranolol hydrochloride
Solubility
DMSO : ≥ 150 mg/mL(507.10 mM ) H2O : 33.33 mg/mL(112.68 mM;Need ultrasonic)
Storage
4℃, sealed storage, away from moisture
Shipping
Room temperature in continental US; may vary elsewhere.
SMILES
OC(CNC(C)C)COC1=CC=CC2=CC=CC=C12.Cl
In Vivo
Propranolol hydrochloride (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant.
In Vitro
Propranolol hydrochloride (10-7 M-10-3 M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10-5 M in HemSCs.Propranolol hydrochloride (10-9 M-10-3 M; 24 and 48 hours) significant decreases cell proliferation at 10-4 M propranolol after 24 hours and 10-9 M propranolol after 48 hours in HemSCs.Propranolol hydrochloride (50 μM-200 μM; 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces HemSC apoptosis.
Datasheet 
